GlobeNewswire

Placetel is named as a leading UC solution in Germany by ISG Experton Group

Dela
  • Placetel, Powered by BroadSoft, named as a leader in the "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS"
  • Study recognizes broad functional spectrum and strong focus on SMEs
  • Operation of data centers in Germany is acknowledged as a further advantage

COLOGNE, Germany, July 24, 2017 (GLOBE NEWSWIRE) --  Placetel, a cloud PBX service from BroadSoft Germany GmbH, has been named by ISG/Experton Group, a leading fully integrated research, advisory and consulting company, as one of the best cloud-based solutions for Unified Communications as a Service (UCaaS) in Germany. ISG/Experton Group positioned Placetel, powered by BroadSoft, in the leadership quadrant in its provider comparison "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS".

An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/38c74af2-ebc5-4f44-9e54-390eea52e0d0

Oliver Giering, Advisor of ISG/Experton Group and lead advisor of the study said: "Placetel has developed very well over the previous year and is therefore represented among some major players in the Leadership Quadrant of our study. In the rapidly growing UC market, there is still great potential for the Placetel offering."

Peter Nowack, general manager and vice president, BroadCloud Retail explains: "UCaaS is becoming the new core of business communications. Therefore, we are particularly proud of this recognition from ISG. Our position in the leadership quadrant further confirms the opportunity to expand our solutions and align them closely to the needs and demanding requirements of our customers."

Not only did ISG praise the Placetel offering for its broad functional spectrums, but also BroadSoft Germany's large customer base for PBX systems from the cloud, as well as its strong focus on medium-sized enterprises. According to ISG, new solutions for business communication have been on the rise, especially for small and medium-sized companies - not least due to the changeover from ISDN to the All-IP network. In addition, the consulting firm appreciated that Placetel is operated via computer centers in Germany.  "For many of our customers, this is particularly important for data availability and security," said Peter Nowack.

Due to market trends and strong growth, ISG has evaluated the UCaaS topic for the first time this year. UCaaS means the cloud-based integration of various communication channels, collaboration solutions and other applications on a single platform. Thus, UCaaS is of crucial importance for modern business communication.

Find further information of the study at www.placetel.de/cloudleader2017

Details of the study

On the basis of the provider comparison "Cloud Transformation / Operation Services & XaaS ISG Vendor Benchmark 2017, the Experton Group is able to provide in its meanwhile 8th edition a detailed and differentiated overview of the most important cloud providers in the German-speaking market to CIOs and IT managers. Furthermore, the study provides effective support in order to evaluate and select suitable cloud vendors and providers. It comprises twelve market categories for Germany as well as six market categories for Switzerland and evaluates more than 150 relevant suppliers.

About Placetel

Placetel is a leading cloud PBX offering, which is provided by BroadSoft Germany GmbH, a subsidiary of BroadSoft, Inc. The multiple award-winning Placetel telephone system is primarily aimed at small and medium-sized businesses. More than 15,000 business customers have already opted for the Placetel cloud PBX solution, which contains more than 150 powerful features and is characterized by its high level of flexibility. According to ISG Experton Group, Placetel is one of the best cloud-based offerings for Unified Communications as a Service (UCaaS) in Germany. For more information about Placetel please click here: www.placetel.de | Twitter | LinkedIn | Placetel Blog

About BroadSoft, Inc.

BroadSoft, Inc. (NASDAQ:BSFT) is the technology innovator in cloud unified communications, team collaboration, and contact center solutions for businesses and service providers across 80 countries. We are the market share leader for cloud unified communications with an open, mobile and secure platform trusted by 25 of the world's top 30 service providers by revenue. Our BroadSoft Business application suite empowers users and teams to share ideas and work simply to achieve breakthrough performance. For additional information, visit www.BroadSoft.com.

Twitter | LinkedIn | BroadSoft Blog

Presse-Kontakt:
Placetel / BroadSoft Germany GmbH
Franziska Huschka
Lothringer Straße 56
50677 Köln
Deutschland
Tel.: +49 221-9999 856 0
E-Mail: fhuschka@broadsoft.com
Internet: www.placetel.de

PR-Agentur:
Donner & Doria Public Relations GmbH
Daniel Impertro
Gaisbergstraße 16
D-69115 Heidelberg
Telefon: +49 6221-58787-34
E-Mail: daniel.impertro@donner-doria.de
Internet: www.donner-doria.de

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BroadSoft, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum